Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers to Use Cell Signaling Technology's PhosphoScan in Drug Study

NEW YORK (GenomeWeb News) – Cell Signaling Technology today said that Bristol-Myers Squibb will use its PhosphoScan technology in cell and tumor phospho-profiling of a small molecule kinase inhibitor.
 
The PhosphoScan process involves immunoaffinity purification and tandem mass spectrometry. It will be applied to in vivo phosphorylation profiling of kinase inhibitor response profiles in xenograft tumor models.
 
Danvers, Mass.-based CST said that the signatures generated with the Bristol-Myers compound will be analyzed within the context of its PhosphoSignature database, which covers hundreds of cell lines and human tumors.
 
The firms signed this agreement following an evaluation period for the technology, which ended in March 2007.
 
Terms of the alliance were not disclosed.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.